The Hematologic Malignancies Program (HMP) is composed of 51 scientists, and clinical investigators from 7 departments at Mayo Clinic in Rochester, MN (MCR), Arizona (MCA), and Florida (MCF). The Program is co- led by Drs. Ansell (MCR), Bergsagel (MCA) and Chanan-Khan (MCF). The HMP aims are to 1) investigate the epidemiology of hematologic malignancies and mechanisms of progression, 2) characterize the molecular and cell biology of hematologic malignancies to identify new therapeutic targets, and 3) develop and test new therapies. To accomplish these aims, the HMP is organized into 4 disease groups (DGs) that are composed of basic and translational research scientists, hematopathologists, and clinicians. The DGs meet weekly or biweekly to discuss research results, clinical trial activities, and requests for use of biobank samples and ensure that research is meeting the needs of the patients in our catchment area. Annual peer-reviewed direct funding to HMP members is $4.6M, with 93% from the National Cancer Institute. This includes 2 SPOREs (Lymphoma and Multiple Myeloma), 15 R01s, 2 R41s, 1 R21, 1 U54, 5 Multiple Myeloma Research Foundation and 2 Leukemia and Lymphoma Society grants. Since 2012, the HMP has recruited 10 new scientists who focus on key research areas ranging from cell signaling to cancer survivorship. Major scientific contributions by the HMP since 2012 include a major role in the approval of nivolumab in Hodgkin lymphoma, leadership in genome wide association studies (GWAS) identifying susceptibility loci in large cell lymphoma, leadership in trials establishing the role of ibrutinb in CLL, and leadership in trials including bortezomib in frontline therapy for multiple myeloma. The HMP continues to have a robust clinical trials program that enrolls over 500 patients each year to therapeutic clinical trials. Members have contributed 1172 publications to the literature since 2013, 43% of which are intraprogrammatic and 30% interprogrammatic. HMP members have extensive collaborations with members in the Gene and Virus Therapy, Experimental Therapeutics, and Genetic Epidemiology and Risk Assessment Programs. HMP members make extensive use of numerous Shared Resources, with substantial use of Biospecimens Accessioning & Processing, Biostatistics, and Pharmacy. Significant institutional and philanthropic (Predolin Foundation) support continues for HMP-related research. In the next funding period, we will mentor young investigators and focus on developing tools to integrate genomic information into the individual care plans for our patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113611
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567

Showing the most recent 10 out of 1129 publications